2269 Stock Overview
WuXi Biologics (Cayman) Inc. bietet End-to-End-Lösungen und -Dienstleistungen für die Erforschung, Entwicklung und Herstellung von Biologika in der Volksrepublik China, Nordamerika, Europa und auf internationaler Ebene.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
WuXi Biologics (Cayman) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$13.36 |
| 52 Week High | HK$56.70 |
| 52 Week Low | HK$12.90 |
| Beta | 0.62 |
| 1 Month Change | -38.57% |
| 3 Month Change | -51.51% |
| 1 Year Change | -71.78% |
| 3 Year Change | -86.90% |
| 5 Year Change | -50.88% |
| Change since IPO | 41.88% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04
Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease
Aug 02Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Jun 29What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
May 16Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today
May 03Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Apr 21An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 42% Undervalued
Mar 26Why We're Not Concerned Yet About WuXi Biologics (Cayman) Inc.'s (HKG:2269) 30% Share Price Plunge
Feb 09Shareholder Returns
| 2269 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -6.6% | -1.0% | 1.7% |
| 1Y | -71.8% | -61.4% | -12.5% |
Rendite im Vergleich zur Industrie: 2269 unter dem Niveau der Branche Hong Kong Life Sciences , die im vergangenen Jahr eine Rendite von -63.1% erzielte.
Rendite vs. Markt: 2269 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von -16.4 erzielte.
Price Volatility
| 2269 volatility | |
|---|---|
| 2269 Average Weekly Movement | 15.3% |
| Life Sciences Industry Average Movement | 11.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.3% |
| 10% least volatile stocks in HK Market | 3.7% |
Stabiler Aktienkurs: 2269Der Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.
Volatilität im Zeitverlauf: 2269Die wöchentliche Volatilität (15%) war im letzten Jahr stabil, liegt aber immer noch höher als bei 75% der Hong Kong Aktien.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 12,740 | Chris Chen | https://www.wuxibiologics.com |
WuXi Biologics (Cayman) Inc. bietet End-to-End-Lösungen und -Dienstleistungen für die Erforschung, Entwicklung und Herstellung von Biologika in der Volksrepublik China, Nordamerika, Europa und international. Darüber hinaus bietet das Unternehmen Beratungsdienste in Bezug auf biopharmazeutische Technologien, internationale Vertriebsverträge, Tests und die Entwicklung von Testtechnologien, Vertriebs- und Marketingdienste sowie klinische und Herstellungsdienste für Biologika, die Produktion und den Verkauf von Arzneimitteln, die Auftragsentwicklung und -herstellung von Impfstoffen (CDMO) und damit zusammenhängende Geschäfte sowie Materiallieferungen. Das Unternehmen hat einen Forschungsdienstleistungsvertrag mit BioNTech SE zur Entdeckung und Erforschung monoklonaler Antikörper für die Entwicklung von therapeutischen Produktkandidaten der nächsten Generation.
WuXi Biologics (Cayman) Inc. Fundamentals Summary
| 2269 fundamental statistics | |
|---|---|
| Market cap | HK$55.74b |
| Earnings (TTM) | HK$3.68b |
| Revenue (TTM) | HK$18.43b |
15.1x
P/E Ratio3.0x
P/S RatioIs 2269 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2269 income statement (TTM) | |
|---|---|
| Revenue | CN¥17.03b |
| Cost of Revenue | CN¥10.21b |
| Gross Profit | CN¥6.83b |
| Other Expenses | CN¥3.43b |
| Earnings | CN¥3.40b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.81 |
| Gross Margin | 40.08% |
| Net Profit Margin | 19.96% |
| Debt/Equity Ratio | 4.9% |
How did 2269 perform over the long term?
See historical performance and comparison